Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164461 | 0.80 | CYP2D6 (0.74) | TSHRKMT2AMEN1CYP2D6CYP2C9 | |
| SCHEMBL498795 | 0.77 | KEAP1 (0.46) | KMT2AHTTMEN1SMN1; SMN2LMNA | |
| SCHEMBL498420 | 0.77 | HDAC1 (0.47) | KMT2ASMN1; SMN2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23052533 | 0.76 | CYP2D6 (0.72) | TSHRKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL20739941 | 0.75 | DPP4 (0.50) | KMT2AMEN1SMN1; SMN2LMNAHDAC1 | |
| SCHEMBL27601052 | 0.75 | CYP2D6 (0.70) | TSHRKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL11051510 | 0.74 | KMT2A (0.61) | TSHRKMT2AHTTMEN1SMN1; SMN2 | |
| SCHEMBL498673 | 0.72 | KDM4E (0.56) | KMT2AMEN1SMN1; SMN2LMNAHDAC1 | |
| SCHEMBL5652601 | 0.70 | CYP2D6 (0.79) | TSHRCYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL9201170 | 0.70 | DPP4 (0.50) | TSHRKMT2AHTTMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8968715-B2 | Drug delivery systems for photodynamic therapy | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| EP-1357912-B1 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-04-25 | — | — | EP | disclosed |
| US-20120041356-A1 | PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE | QLT INC. (CA) | 2012-02-16 | — | — | US | disclosed |
| US-8106038-B2 | Method for reducing or preventing PDT related inflammation | QLT INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| EP-2379109-A1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | Qlt Inc. (CA) | 2011-10-26 | — | — | EP | disclosed |
| US-8034803-B2 | Treating an occult choroidal neovascular lesion | QLT INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| US-20020173832-A1 | Reduced fluence rate PDT | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | BAUSCH HEALTH COMPANIES INC. (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-10-24 | — | — | US | disclosed |
| WO-2002083097-A2 | DRUG DELIVERY SYSTEM FOR HYDROPHOBIC DRUGS | QLT INC. (CA) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062385-A2 | METHOD TO PREVENT VISION LOSS | QLT, INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| EP-1229937-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT Inc. (CA) | 2002-08-14 | — | — | EP | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001035996-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | LIPA, MLEC, ABCG2 | TSHR 1700/4885KMT2A 3473/4885HTT 39/4885 |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | PIN1, PPOX, DHFR | TSHR 4217/4885KMT2A 2658/4885HTT 409/4885 |
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | TSHR 4473/4885KMT2A 2286/4885HTT 2725/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | TSHR 3569/4885KMT2A 2520/4885HTT 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.